ArticleCureus2026
Real-World Outcomes of Colorectal Signet Ring Cell Carcinoma: Clinicopathological Characteristics, Treatment Patterns, and Survival.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal signet-ring cell carcinoma (SRCC) is a rare and aggressive histological subtype of colorectal cancer (CRC) characterised by advanced stage at presentation and poor prognosis. Data from the Indian subcontinent remain limited. This study aimed to evaluate the clinicopathological characteristics, treatment patterns, prognostic factors, and survival outcomes of patients with colorectal SRCC treated at a tertiary cancer centre.
methodsA retrospective observational study was conducted, including patients with histologically confirmed colorectal SRCC treated at a tertiary cancer centre. Demographic, clinical, pathological, treatment, and survival data were collected. Overall survival (OS) was estimated using the Kaplan-Meier method. Prognostic factors associated with OS were evaluated using univariate and multivariable Cox proportional hazards regression analyses.
resultsA total of 263 patients were included. The median age was 37 years (IQR, 28.5-49), with 58.2% of patients younger than 40 years, and males constituted 63.1% of the cohort. The rectum was the predominant primary site (73.4%), and 93.2% of patients presented with stage III or IV disease. Curative-intent treatment was performed in 73.8% of patients, with total neoadjuvant therapy followed by surgery being the most common treatment strategy (27.2%). Among patients receiving neoadjuvant treatment, a complete response was achieved in 11.0%, whereas disease progression occurred in 22.9%. Recurrence developed in 48.6% of surgically treated patients, with the peritoneum representing the most common site of recurrence (36.4%). After a median follow-up of 35 months, the median DFS was 21 months (95% CI: 15.8-26.1), with a two-year DFS rate of 40.3±4.5%, while the median OS was 30 months (95% CI: 26.1-33.9) with a two-year OS rate of 62.1±4.4%. On univariate analysis, positive lymph node status, lymphovascular invasion, perineural invasion, positive resection margins, and elevated baseline carcinoembryonic antigen (CEA) were significantly associated with worse OS, whereas neoadjuvant therapy was associated with improved survival. In multivariable analysis, pathological nodal stage, positive resection margins, and elevated baseline CEA showed trends towards poorer survival but did not reach statistical significance.
conclusionColorectal SRCC predominantly affects young patients and presents at an advanced stage with aggressive clinicopathological features and poor oncological outcomes. Advanced nodal disease, adverse pathological features, and elevated baseline CEA were associated with inferior survival. Early diagnosis, multidisciplinary management, and prospective multicentre studies incorporating comprehensive molecular profiling are required to improve outcomes in this challenging disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.